| Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 … VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... The lancet Respiratory medicine 9 (12), 1407-1418, 2021 | 665 | 2021 |
| Increased risk of influenza among vaccinated adults who are obese SD Neidich, WD Green, J Rebeles, EA Karlsson, S Schultz-Cherry, ... International journal of obesity 41 (9), 1324-1330, 2017 | 265 | 2017 |
| Reducing the blood pressure–related burden of cardiovascular disease: impact of achievable improvements in blood pressure prevention and control ST Hardy, LR Loehr, KR Butler, S Chakladar, PP Chang, AR Folsom, ... Journal of the American Heart Association 4 (10), e002276, 2015 | 187 | 2015 |
| Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or … EW Ely, AV Ramanan, CE Kartman, S de Bono, R Liao, MLB Piruzeli, ... The Lancet Respiratory Medicine 10 (4), 327-336, 2022 | 160 | 2022 |
| Heterogeneity in blood pressure transitions over the life course: age-specific emergence of racial/ethnic and sex disparities in the United States ST Hardy, KM Holliday, S Chakladar, JC Engeda, NB Allen, G Heiss, ... JAMA cardiology 2 (6), 653-661, 2017 | 40 | 2017 |
| LB3. Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: Results of a Randomized … EW Ely, AV Ramanan, CE Kartman, S de Bono, R Liao, MLB Piruzeli, ... Open forum infectious diseases 8 (Supplement_1), S808-S809, 2021 | 34 | 2021 |
| Baricitinib plus standard of care for hospitalized adults with COVID-19 VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... MedRxiv, 2021 | 28 | 2021 |
| Efficacy and safety of baricitinib in patients with COVID-19 infection: results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... MedRxiv, 2021.04. 30.21255934, 2021 | 22 | 2021 |
| COV-BARRIER Study Group: Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group … VC Marconi, AV Ramanan, S de Bono, CE Kartman, V Krishnan, R Liao, ... Lancet Respir Med 9 (12), 1407-1418, 2021 | 21 | 2021 |
| Disparities in early transitions to obesity in contemporary multi-ethnic US populations CL Avery, KM Holliday, S Chakladar, JC Engeda, ST Hardy, JP Reis, ... PloS one 11 (6), e0158025, 2016 | 17 | 2016 |
| Baricitinib and primary biliary cholangitis SC Gordon, S Trudeau, A Regev, JM Uhas, S Chakladar, A Pinto-Correia, ... Journal of Translational Autoimmunity 4, 100107, 2021 | 12 | 2021 |
| Reducing the Blood Pressure–Related Burden of Cardiovascular Disease: Impact of Achievable Improvements in Blood Pressure Prevention and Control. J Am Heart Assoc. 2015; 4 … ST Hardy, LR Loehr, KR Butler, S Chakladar, PP Chang, AR Folsom, ... | 11 | |
| Discrete time multistate model with regime switching for modeling COVID-19 disease progression and clinical outcomes S Chakladar, R Liao, W Landau, M Gamalo, Y Wang Statistics in Biopharmaceutical Research 14 (1), 52-66, 2022 | 7 | 2022 |
| Inverse Probability Weighted Estimators of Vaccine Effects Accommodating Partial Interference and Censoring S Chakladar, MG Hudgens, ME Halloran, JD Clemens, M Ali, ME Emch Biometrics, 1– 12. https://doi.org/10.1111/biom.13459, 2019 | 7 | 2019 |
| Targeting physical activity interventions for adults: When should intervention occur? KM Holliday, DY Lin, S Chakladar, SF Castañeda, ML Daviglus, ... Preventive medicine 97, 13-18, 2017 | 6 | 2017 |
| Transitions from ideal to intermediate cholesterol levels may vary by cholesterol metric JC Engeda, KM Holliday, ST Hardy, S Chakladar, DY Lin, GA Talavera, ... Scientific reports 8 (1), 2782, 2018 | 5 | 2018 |
| A quantile-based method for association mapping of quantitative phenotypes: an application to rheumatoid arthritis phenotypes S Ghosh, KR Sanapala, A Ghosh, S Chakladar BMC proceedings 3, 1-4, 2009 | 4 | 2009 |
| Early Loss of Normal Body Weight in Multiethnic US Populations: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL), Strong Heart Family Study (SHFS), and the … CL Avery, KM Holliday, S Chakladar, DY Lin, AE Moncrieft, RJ Ostfeld, ... Circulation 131 (suppl_1), A33-A33, 2015 | 3 | 2015 |
| Estimands, handling of missing data and impact on assumed effect size and power in pivotal COVID-19 treatment trials S Chakladar, R Liao, M Gamalo Journal of Biopharmaceutical Statistics 33 (4), 403-424, 2023 | 2 | 2023 |
| Win ratio approach for analyzing composite time‐to‐event endpoint with opposite treatment effects in its components R Liao, S Chakladar, M Gamalo Pharmaceutical Statistics 21 (6), 1342-1356, 2022 | 2 | 2022 |
Christy AveryUniversity of North CarolinaVerified email at unc.edu
